EUCTR2011-001720-37-IT进行中（未招募）不适用
Multi-centre, phase II, single arm study of the docetaxel, oxaliplatin, capecitabine (DOC) combination in untreated patients with advanced or metastatic gastric cancer - DOC2
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Age =18, - Histologically or cytologically confirmed adenocarcinoma of the stomach or lower third of the oesophagus, - HER2/NEU status as negative (IHC 1-2+; FISH negative). - Clinical stage: T4 N-/+ M0 or TxNxM1; local relapse not amenable to curative surgery. - The stage classification is clinical and will be defined by the most appropriate method (Physical exam, EGDS, EUS, CT, MRI). - ECOG Performance Status of 0 or 1. - Royal Marsden Hospital prognostic index, Group 1(See appendix). - No previous chemotherapy for advanced or locally relpsed disease. - Previous adjuvant chemotherapy completed at least 6 months before registration. - Measurable/evaluable disease, according to the (NCI-CTCAE v.3) criteria. - Baseline laboratory values: absolute neutrophil count (ANC) =2000/mm3, hemoglobin >10.0 g/dL, platelet count =100,000/mm3??creatinine <1.5 times the upper limit of normal (ULN); in case of threshold values the creatinine clearance will be evaluated according to the Cockroft-Gault formula and should be > 60 ml/min, transaminases <2.5 times ULN, alkaline phosphatase < 2.5 times ULN, total bilirubin < 1.0 times ULN. -Signed written informed consent. -Patient willing and able to comply with protocol requirements. -Life expectancy > 3 months. -Recovery from acute effects of surgery.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 21
排除标准
- •- HER2+ positivity (immunohistochemistry 3+ or fluorescence in situ hybridization–amplified). -Previous chemotherapy for metastatic or relapsed disease. -New York Heart Association Class 3 or 4 heart disease. -Clinically significant heart disease, including but not limited to: myocardial infarction within the last 6 months, congestive heart failure, unstable angina, clinically significant pericardial effusion or serious arrhythmia. -Peripheral neuropathy grade = 2 according to the NCI-CTCAE v.3. -Any serious active infection (uncontrolled or requiring treatment). -Any history or evidence of CNS disease, e.g. brain metastases. -Any known hypersensitivity to study drug components. -Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, or inability to take oral medication. -Pregnant or lactating women. -Fertile patients (male and female) unwilling to use effective means of contraception during the study.
研究者
相似试验
进行中（未招募）
不适用
A phase 2a, multi-centre, controlled study of the safety and efficacy of wound healing gel I-020502 in patients undergoing autologous meshed skin grafting. - Acute WoundsEUCTR2006-005092-18-DEKUROS BIOSURGERY AG10
进行中（未招募）
不适用
A multi-centre, open-label, phase II study of the safety, efficacy and pharmacokinetic (PK) profile of CAP-232 administered through continuous intravenous infusion in patients with metastatic kidney cancerEUCTR2006-004857-86-FRCaprion Pharmaceuticals Inc.40
进行中（未招募）
1 期
A multicenter phase II, single arm study of Durvalumab (MEDI 4736) with Carboplatin plus Etoposide for 4 cycles followed by Durvalumab maintenance in patients with metastatic pulmonary large-cell neuroendocrine carcinoma (LCNEC) - DUPLE trialtreatment-naïve patients with metastatic pulmonary large-cell neuroendocrine carcinoma (LCNEC)MedDRA version: 20.0Level: PTClassification code 10071542Term: Neuroendocrine carcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-005942-41-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC)49
已完成
2 期
Multicenter Phase II Clinical Study of the research on optimal assessments and treatment strategy of nilotinib in newly diagnosed chronic myelogenous leukemia patients in the chronic phase (CML-CP) based on early achievement of complete molecular response (CMR); N-roadChronic Myelogenous LeukemiaJPRN-UMIN000008565Cooperative study between Jikei University Kashiwa Hospital and Shimousa Hematology Study Group50
进行中（未招募）
1 期
Phase 1b/2 study of rogaratinib (BAY 1163877) in combination with atezolizumab in urothelial carcinomaFGFR-positive locally advanced or metastatic urothelial carcinomaMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2017-001483-38-ATBayer AG210